Article
Personalized synthetic lethality induced by targeting RAD52 in leukemias identified by gene mutation and expression profile.
Blood - 15 Aug 2013
Cramer-Morales Kimberly, Nieborowska-Skorska Margaret, Scheibner Kara, Padget Michelle, Irvine David A, Sliwinski Tomasz, Haas Kimberly, Lee Jaewoong, Geng Huimin, Roy Darshan, Slupianek Artur, Rassool Feyruz V, Wasik Mariusz A, Childers Wayne, Copland Mhairi, Müschen Markus, Civin Curt I, Skorski Tomasz
Abstract excerpt
Homologous recombination repair (HRR) protects cells from the lethal effect of spontaneous and therapy-induced DNA double-stand breaks. HRR usually depends on BRCA1/2-RAD51, and RAD52-RAD51 serves as back-up. To target HRR in tumor cells, a phenomenon called "synthetic lethality" was applied, which relies on the addiction of cancer cells to a single DNA repair pathway, whereas normal cells operate 2 or more...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.